Netherlands-based company developing a diagnostics platform via leveraging AI to support pathologists with accurate and efficient clinical diagnostics, Aiosyn raised EUR 2 million in recent funding. The company announced the fundraise on December 22, 2022. Utrecht-based Health Innovations led the financing for the firm. Meanwhile, East Netherlands Development Agency Oost NL and Eindhoven-based VC firm LUMO Labs joined in the financing.
Purpose of financing for Aiosyn
With the latest fundraise, Aiosyn intends to further develop its platform.
Besides, it seeks to accelerate its market reach and its operations. Recently, the company received ISO:13485 certification as a first step towards developing high-quality AI-based medical devices. In addition, it seeks to fuel product launches and prepare for the future product roadmap.
What the company’s co-founder has to say
Patrick de Boer, CEO and co-founder of Aiosyn, said, “The field of pathology is challenged by a growing workload and a shortage of pathologists. Aiosyn develops algorithms that work in close synergy with pathologists to improve the digital.”
What the investors have to add
Björn Schaap, investment manager of Health at Oost NL, further said, “Aiosyn’s pioneering platform technology has the potential to push the boundaries within pathology. Making the diagnosis of diseases more accurate, timely, and relevant increases efficiency and gives the pathologist more time to focus on complex analyses. Therefore, it is my belief that the algorithms the Aiosyn team, a spin-out from Radboudumc, is developing will benefit patients. The tremendous development Aiosyn has made in the last year solidifies this belief, and for this reason, the company has the support of Oost NL.”
In addition, Sven Bakkes, partner at LUMO Labs, added, “We have noticed an uptake of AI in the healthcare industry in 2022. It is great to see the Aiosyn team making substantial progress and reaching this major milestone, securing this new round after our initial investment through the TTT.AI pre-seed fund. It will allow them to take the essential next steps on their way to making an impact on healthcare professionals and patients. We’ll be there to support them.”
Besides, Yvonne Sijm, investment manager at Health Innovations, said, “We believe that digital innovations enable the future of healthcare. Pathology plays an increasingly important role in many patient journeys. The solutions developed by Aiosyn support pathologists in providing high-quality decision-making. Aiosyn prepares the labour-intensive routine pathology tasks so that the pathologist can focus on the more interesting and complex tasks. This way, computational pathology not only makes life easier for pathologists, but it also helps in addressing the scarcity challenges.”
About the company
In 2021, Founders David Tellez, Jeroen van der Laak, Patrick de Boer, and Wouter Bulten launched the company. Aiosyn is a spin-off from the Computational Pathology Group of the Radboudumc in Nijmegen, the Netherlands.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
